Laura Sepp-Lorenzino

Laura Sepp-Lorenzino currently works at Lexeo Therapeutics, Inc., as Director from 2026, Oligonucleotide Therapeutics Society, Inc., as Director, Alliance for Regenerative Medicine, as Director, and Taysha Gene Therapies, Inc., as Independent Director from 2020.
Dr. Sepp-Lorenzino also formerly worked at Merck & Co., Inc., as Executive Director & Head-RNA Therapeutics from 1999 to 2014, Vertex Pharmaceuticals, Inc., as VP, Head-Nucleic Acid Therapies & Research from 2017 to 2019, Alnylam Pharmaceuticals, Inc., as Vice President from 2014 to 2017, and Intellia Therapeutics, Inc., as Chief Scientific Officer & Executive VP from 2019 to 2025.
Dr. Sepp-Lorenzino received her graduate degree and doctorate degree from New York University and undergraduate degree from Universidad de Buenos Aires.